GHRS vs ADRX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
GHRS · GH Research$18.61 ▲ 0.92%
ADRX · Adarx Pharmaceuticals$13.23 ▼ 0.45%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- GHRS -21.9%
- ADRX -31.6%
Head to head
| Metric | GHRS | ADRX |
|---|---|---|
| Price | $18.61 | $13.23 |
| Change today | ▲ 0.92% | ▼ 0.45% |
| Market cap | $1.28B | $1.35B |
| Return, 3 months | -37.0% | – |
| Return, year to date | +46.5% | – |
| Return, 1 year | +37.9% | – |
| P/E (TTM) | – | – |
| P/B | 3.6 | -5.4 |
| P/E percentile vs own 5y | 45th | 87th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +258.7% |
| Net profit growth (YoY) | -63.1% | -42.4% |
| Gross margin | – | – |
| Operating margin | – | -1,735.0% |
| Net margin | – | -1,434.1% |
| Return on equity | -18.8% | – |
| Analyst target vs. price | +133.1% | +164.6% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 37 | 22 |
| 30-day volatility | 55.8% | 60.6% |
| Max drawdown, 1 year | -41.0% | -35.9% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ADRX is the largest of the group by market value.
- GHRS has been the calmest stock over the last 30 days.